RYTM Rhythm Pharmaceuticals, Inc.
RYTM Rhythm Pharmaceuticals, Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 neutral converging
POC $89.41 · VWAP $99.48 · -13.4% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster EVP, Officer + 2 others sold $17M, Aug 14–17
Coverage
1 watchlist
RYTM Price Structure
Loading timeframes…
Peers
Every watchlist RYTM belongs to, members best 30-day change first — RYTM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@peptide-economy
Reported the quarter ending 2026-06-30: revenue $71M, diluted EPS -$0.73, net income -$49M (SEC filing). Across the print the stock moved +7.7% (close before → first close after).
full note →Against street estimates
How RYTM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about RYTM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled today · Oct 17
- RYTM.B - | Stock Price & Latest News
- Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Report
- Investor Overview – Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update – Rhythm Pharmaceuticals, Inc.
- Rhythm Pharmaceuticals Q2 2026 Earnings Results & Report
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
RYTM research tape
56 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.